Navigation Links
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
Date:6/5/2008

dications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its program for MPS IVA, and expectations regarding filings with regulatory agencies. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of current and planned clinical trials related to the enzyme replacement therapy for MPS IVA; the content and timing of decisions by the U.S. Food and Drug Administration and other regulatory agencies, particularly with respect to the enzyme replacement therapy for MPS IVA, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10- K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme(R) is a registered trademark of BioMarin/Genzy
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin to Host Research and Development Day June 5th
2. BioMarin to Present at the Bank of America Healthcare Conference
3. BioMarin Announces First Quarter 2008 Financial Results
4. BioMarin to Present at the Morgan Stanley Healthcare Conference
5. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
6. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
9. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
10. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
11. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... -- "Everybody is affected by cancer sooner or later," Dr. ... We,ve got to get away from that."  If you,ve ... loved one or friend battling for their life against ... other treatments cause the human body. It,s almost enough ... succumb to the disease. Dr. Dionne has developed a ...
(Date:4/20/2015)... , April 20, 2015   Meditope Biosciences, Inc ... its proprietary technology, today announced presentation of data demonstrating ... development of antibody-drug conjugates (ADCs). The data were presented in ... place April 18-22 in Philadelphia . ... data which point to the many commercial applications that ...
(Date:4/17/2015)... April 17, 2015  Centrillion Technologies, a ... grant from the National Human Genome Research ... Health (NIH). The grant will help fund ... development of breakthrough genomic technologies, including phased ... substrates. Centrillion has been developing this transformative ...
(Date:4/17/2015)... 17, 2015  Guggenheim Securities, the investment banking and ... hiring of William Tanner as a Managing ... Tanner will start work at Guggenheim in May 2015 ... office. "Bill brings a wealth of biotech ... experienced and highly acclaimed healthcare team," said Matthew ...
Breaking Biology Technology:Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2
... Tengion Inc., a clinical stage regenerative medicine company focused on ... M.D., President and Chief Executive Officer of Tengion, will present at ... 2008 at 9:50 a.m. EST at The Palace Hotel in New ... About Tengion , , ...
... 25 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today ... the three-month period ended September,30, 2008. The Company will ... eastern time (details follow below). , ... $77.8 million,an increase of 18% from fiscal 2007 revenues of ...
... ANN ARBOR, Mich., Nov. 24 Terumo Heart, Inc. ... the position of Chief Executive,Officer (C.E.O.) and President, effective ... for a strong leadership role in,the future treatment of ... enrollment in the DuraHeart U.S. Pivotal trials in up ...
Cached Biology Technology:Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 2Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 3Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 4Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 5Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 6Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 7Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 8Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 9Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 10Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 11Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President 2
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... The psychological impact of natural disasters such as ... people inherently respond to unpredictable situations, according to a ... Dr Magda Osman, Psychology Lecturer at Queen Mary, University ... Learning in Complex Worlds, said the disaster had a ...
... pager or cell phone three times, that would be your best ... simple tissue moistened with saline would do the trick. But if ... phone you,d be better off reaching for a disinfectant wipe. ... that appeared online in PubMed , with the discoveries having ...
... observe behavior in fossil specimens that are dead even ... modern, living, species that has some similarities to the ancient ... University of Cincinnati professor of geology and colleagues as they ... they resemble clams or other shelled mollusks, brachiopods are more ...
Cached Biology News:Psychological impact of Japan disaster will be felt 'for some time to come' 2Bacterial wipes research study 2Paleontologists audition modern examples of ancient behavior 2
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
...
Biology Products: